Galen EB Wright | Wright Lab Neurogenomics Researchhttps://galenwrightlab.com/author/galen-eb-wright/Galen EB WrightWowchemy (https://wowchemy.com)en-usThu, 07 Dec 2023 22:05:16 +0000https://galenwrightlab.com/media/icon_hud8d3e7dee30ca0d2b7c46a569b885cc2_13345_512x512_fill_lanczos_center_3.pngGalen EB Wrighthttps://galenwrightlab.com/author/galen-eb-wright/Characterisation of CYP2B6 and CYP2A6 pharmacogenetic variation in sub-Saharan African populationshttps://galenwrightlab.com/publication/twesigomwe-2023-characterisation/Thu, 07 Dec 2023 22:05:16 +0000https://galenwrightlab.com/publication/twesigomwe-2023-characterisation/A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancyhttps://galenwrightlab.com/publication/hippman-2022-cross/Sat, 01 Jan 2022 00:00:00 +0000https://galenwrightlab.com/publication/hippman-2022-cross/A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant womenhttps://galenwrightlab.com/publication/drogemoller-2022-pharmacogenomic/Sat, 01 Jan 2022 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2022-pharmacogenomic/A systematic review and analysis of the use of polygenic scores in pharmacogenomicshttps://galenwrightlab.com/publication/johnson-2022-systematic/Sat, 01 Jan 2022 00:00:00 +0000https://galenwrightlab.com/publication/johnson-2022-systematic/Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populationshttps://galenwrightlab.com/publication/twesigomwe-2022-characterization/Sat, 01 Jan 2022 00:00:00 +0000https://galenwrightlab.com/publication/twesigomwe-2022-characterization/Common huntingtin-related genetic variation is associated with neurobiological and aging traits in humanshttps://galenwrightlab.com/publication/slike-2022-common/Sat, 01 Jan 2022 00:00:00 +0000https://galenwrightlab.com/publication/slike-2022-common/Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis Chttps://galenwrightlab.com/publication/loucks-2022-patient/Sat, 01 Jan 2022 00:00:00 +0000https://galenwrightlab.com/publication/loucks-2022-patient/Integrating disease and drug-related phenotypes for improved identification of pharmacogenomic variantshttps://galenwrightlab.com/publication/ouellette-2021-integrating/Fri, 01 Jan 2021 00:00:00 +0000https://galenwrightlab.com/publication/ouellette-2021-integrating/Integrative neuroinformatics for precision prognostication and personalized therapeutics in moderate and severe traumatic brain injuryhttps://galenwrightlab.com/publication/zeiler-2021-integrative/Fri, 01 Jan 2021 00:00:00 +0000https://galenwrightlab.com/publication/zeiler-2021-integrative/Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatmenthttps://galenwrightlab.com/publication/lin-2021-novel/Fri, 01 Jan 2021 00:00:00 +0000https://galenwrightlab.com/publication/lin-2021-novel/StellarPGx: A Nextflow pipeline for calling star alleles in cytochrome P450 geneshttps://galenwrightlab.com/publication/twesigomwe-2021-stellarpgx/Fri, 01 Jan 2021 00:00:00 +0000https://galenwrightlab.com/publication/twesigomwe-2021-stellarpgx/Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicityhttps://galenwrightlab.com/publication/scott-2021-transcriptome/Fri, 01 Jan 2021 00:00:00 +0000https://galenwrightlab.com/publication/scott-2021-transcriptome/A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: a focus on CYP2D6 genotypinghttps://galenwrightlab.com/publication/twesigomwe-2020-systematic/Wed, 01 Jan 2020 00:00:00 +0000https://galenwrightlab.com/publication/twesigomwe-2020-systematic/Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance rangehttps://galenwrightlab.com/publication/findlay-2020-frequency/Wed, 01 Jan 2020 00:00:00 +0000https://galenwrightlab.com/publication/findlay-2020-frequency/Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington diseasehttps://galenwrightlab.com/publication/wright-2020-gene/Wed, 01 Jan 2020 00:00:00 +0000https://galenwrightlab.com/publication/wright-2020-gene/Huntington diseasehttps://galenwrightlab.com/publication/caron-2020-huntington/Wed, 01 Jan 2020 00:00:00 +0000https://galenwrightlab.com/publication/caron-2020-huntington/Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapieshttps://galenwrightlab.com/publication/wright-2020-interrupting/Wed, 01 Jan 2020 00:00:00 +0000https://galenwrightlab.com/publication/wright-2020-interrupting/Analyses of adverse drug reactions--nationwide active surveillance network: Canadian pharmacogenomics network for drug safety databasehttps://galenwrightlab.com/publication/tanoshima-2019-analyses/Tue, 01 Jan 2019 00:00:00 +0000https://galenwrightlab.com/publication/tanoshima-2019-analyses/Genome-Wide Association Studies of Drug-Induced Liver Injury Make Progress Beyond the HLA Regionhttps://galenwrightlab.com/publication/wright-2019-genome/Tue, 01 Jan 2019 00:00:00 +0000https://galenwrightlab.com/publication/wright-2019-genome/Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington diseasehttps://galenwrightlab.com/publication/wright-2019-length/Tue, 01 Jan 2019 00:00:00 +0000https://galenwrightlab.com/publication/wright-2019-length/Outcome definition influences the relationship between genetic polymorphisms of ERCC1, ERCC2, SLC22A2 and cisplatin nephrotoxicity in adult testicular cancer patientshttps://galenwrightlab.com/publication/zazuli-2019-outcome/Tue, 01 Jan 2019 00:00:00 +0000https://galenwrightlab.com/publication/zazuli-2019-outcome/Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Researchhttps://galenwrightlab.com/publication/drogemoller-2019-pharmacogenomics/Tue, 01 Jan 2019 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2019-pharmacogenomics/Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy geneshttps://galenwrightlab.com/publication/wright-2019-pharmacogenomics/Tue, 01 Jan 2019 00:00:00 +0000https://galenwrightlab.com/publication/wright-2019-pharmacogenomics/Common variation near IRF6 is associated with IFN-$β$-induced liver injury in multiple sclerosishttps://galenwrightlab.com/publication/kowalec-2018-common/Mon, 01 Jan 2018 00:00:00 +0000https://galenwrightlab.com/publication/kowalec-2018-common/CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelineshttps://galenwrightlab.com/publication/drogemoller-2018-cyp-2-d-6/Mon, 01 Jan 2018 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2018-cyp-2-d-6/Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer PatientsThe Role of ACYP2 and WFS1 in Cisplatin-Induced Ototoxicityhttps://galenwrightlab.com/publication/drogemoller-2018-further/Mon, 01 Jan 2018 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2018-further/Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patientshttps://galenwrightlab.com/publication/mccormack-2018-genetic/Mon, 01 Jan 2018 00:00:00 +0000https://galenwrightlab.com/publication/mccormack-2018-genetic/The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general populationhttps://galenwrightlab.com/publication/kay-2018-molecular/Mon, 01 Jan 2018 00:00:00 +0000https://galenwrightlab.com/publication/kay-2018-molecular/Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancerhttps://galenwrightlab.com/publication/drogemoller-2017-association/Sun, 01 Jan 2017 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2017-association/The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin Americahttps://galenwrightlab.com/publication/kay-2017-targetable/Sun, 01 Jan 2017 00:00:00 +0000https://galenwrightlab.com/publication/kay-2017-targetable/CYP2B6*6 and CYP2B6*18 predict long-term efavirenz exposure measured in hair samples in HIV-positive South African womenhttps://galenwrightlab.com/publication/rohrich-2016-cyp-2-b-6/Fri, 01 Jan 2016 00:00:00 +0000https://galenwrightlab.com/publication/rohrich-2016-cyp-2-b-6/The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patientshttps://galenwrightlab.com/publication/drogemoller-2016-identification/Fri, 01 Jan 2016 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2016-identification/Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohorthttps://galenwrightlab.com/publication/dodgen-2015-evaluation/Thu, 01 Jan 2015 00:00:00 +0000https://galenwrightlab.com/publication/dodgen-2015-evaluation/Considerations for rare variants in drug metabolism genes and the clinical implicationshttps://galenwrightlab.com/publication/drogemoller-2014-considerations/Wed, 01 Jan 2014 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2014-considerations/Informed consent and ethical re-use of African genomic datahttps://galenwrightlab.com/publication/wright-2014-informed/Wed, 01 Jan 2014 00:00:00 +0000https://galenwrightlab.com/publication/wright-2014-informed/Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patientshttps://galenwrightlab.com/publication/drogemoller-2014-patterns/Wed, 01 Jan 2014 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2014-patterns/Sequencing of GJB2 in Cameroonians and Black South Africans and comparison to 1000 Genomes Project data support need to revise strategy for discovery of nonsyndromic deafness genes in Africanshttps://galenwrightlab.com/publication/bosch-2014-sequencing/Wed, 01 Jan 2014 00:00:00 +0000https://galenwrightlab.com/publication/bosch-2014-sequencing/Ethical and legal implications of whole genome and whole exome sequencing in African populationshttps://galenwrightlab.com/publication/wright-2013-ethical/Tue, 01 Jan 2013 00:00:00 +0000https://galenwrightlab.com/publication/wright-2013-ethical/Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort studyhttps://galenwrightlab.com/publication/dodgen-2013-introduction/Tue, 01 Jan 2013 00:00:00 +0000https://galenwrightlab.com/publication/dodgen-2013-introduction/Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatmenthttps://galenwrightlab.com/publication/drogemoller-2013-next/Tue, 01 Jan 2013 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2013-next/Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohorthttps://galenwrightlab.com/publication/wright-2012-association/Sun, 01 Jan 2012 00:00:00 +0000https://galenwrightlab.com/publication/wright-2012-association/Chromosome 22q11 in a Xhosa schizophrenia populationhttps://galenwrightlab.com/publication/koen-2012-chromosome/Sun, 01 Jan 2012 00:00:00 +0000https://galenwrightlab.com/publication/koen-2012-chromosome/End of the beginning and public health pharmacogenomics: knowledge in â˜Mode 2â™and P5 medicinehttps://galenwrightlab.com/publication/ozdemir-2012-end/Sun, 01 Jan 2012 00:00:00 +0000https://galenwrightlab.com/publication/ozdemir-2012-end/Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nationhttps://galenwrightlab.com/publication/warnich-2011-pharmacogenomic/Sat, 01 Jan 2011 00:00:00 +0000https://galenwrightlab.com/publication/warnich-2011-pharmacogenomic/Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applicationshttps://galenwrightlab.com/publication/drogemoller-2011-whole/Sat, 01 Jan 2011 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2011-whole/Characterization of the genetic profile of CYP2C19 in two South African populationshttps://galenwrightlab.com/publication/drogemoller-2010-characterization/Fri, 01 Jan 2010 00:00:00 +0000https://galenwrightlab.com/publication/drogemoller-2010-characterization/Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa populationhttps://galenwrightlab.com/publication/wright-2010-elucidation/Fri, 01 Jan 2010 00:00:00 +0000https://galenwrightlab.com/publication/wright-2010-elucidation/